NEW YORK – Myriad Genetics reported after the close of market Monday year-over-year revenue growth of 7 percent for the fourth quarter of 2024 and 11 percent for the full year.

纽约——Myriad Genetics在周一市场收盘后报告称，2024年第四季度营收同比增长7%，全年增长11%。

The Salt Lake City-based genetic testing company also announced that it has appointed Sam Raha, the company's current chief operating officer (COO), as CEO, replacing current CEO Paul Diaz.

总部位于盐湖城的基因检测公司还宣布，已任命公司现任首席运营官（COO）萨姆·拉哈为首席执行官，接替现任首席执行官保罗·迪亚兹。

For the three months ending Dec. 31 Myriad reported $210.6 million in revenues compared to $196.6 million for the same quarter in 2023, driven by 4 percent year-over-year growth in test volumes. The top-line result just beat analysts' average estimate of approximately $210 million.

截至12月31日的三个月，Myriad报告收入为2.106亿美元，相比2023年同期的1.966亿美元，增长了4%的测试量。这一收入结果略高于分析师平均估计的约2.1亿美元。

The company's Q4 hereditary cancer testing revenues rose 6 percent year over year to $94.3 million from $88.9 million. Tumor profiling test revenue fell  4 percent to $30.8 million from $32.1 million in the same quarter last year. Prenatal test sales rose 12 percent to $44.9 million versus $40 million a year ago, and the firm's pharmacogenomics test revenue was up 14 percent to $40.6 million from $35.6 million..

公司第四季度的遗传性癌症检测收入同比增长6%，从8890万美元增加到9430万美元。肿瘤分析检测收入同比下降4%，从去年同期的3210万美元降至3080万美元。产前检测销售额增长了12%，从去年的4000万美元增加到4490万美元，而公司的药物基因组学检测收入增长了14%，从3560万美元增加到4060万美元。

Myriad's Q4 net loss was $42.5 million, or $.47 per share, compared to a loss of $31.2 million, or $.36 per share, in Q4 of last year. On an adjusted basis, the company posted earnings per share of $.03, besting  analysts' average estimate of a $.03 loss per share.

Myriad第四季度净亏损为4250万美元，即每股亏损0.47美元，而去年第四季度的亏损为3120万美元，即每股亏损0.36美元。按调整后计算，该公司每股收益为0.03美元，优于分析师平均预计的每股亏损0.03美元。

Myriad's R&D spending rose 41 percent to $29.7 million from $21 million in the same quarter last year. Its SG&A expenses fell 5 percent to $138.5 million compared to $145.4 million in Q4 of 2023.

Myriad的研发支出从去年同期的2100万美元增长了41%，达到2970万美元。其销售、一般和管理（SG&A）费用下降了5%，从2023年第四季度的1.454亿美元降至1.385亿美元。

In a conference call with investors, Diaz said his departure was a 'personal decision,' explaining that he received an offer to join private equity firm Cressey & Company as a managing partner and adding that Raha 'has done an exceptional job here.' Diaz will continue to serve the company as a consultant to Raha and the board of directors for another year.

在与投资者的电话会议上，迪亚兹表示他的离职是“个人决定”，并解释说他收到了私募股权公司 Cressey & Company 的邀请，将担任管理合伙人一职，同时补充道，拉哈“在这里做得非常出色”。 迪亚兹将继续以顾问身份为拉哈和董事会服务一年。

In addition, Myriad said that current Chief Commercial Officer Mark Verratti will be promoted to COO concurrent with Raha's appointment. .

此外，Myriad表示，现任首席商务官马克·韦拉蒂将在拉哈的任命同时晋升为首席运营官。

Also on the call, Diaz sought to assuage concerns about the company's potential exposure to Medicaid cuts by the Trump administration. Diaz noted that in the event of potential changes to Medicaid, prenatal testing faces the greatest exposure, but noted that state legislatures, which have historically been reluctant to tamper with reimbursement in this area, are likely to provide a measure of insulation.

此外，在电话会议中，迪亚兹试图缓解人们对特朗普政府可能削减医疗补助计划（Medicaid）而对公司造成影响的担忧。迪亚兹指出，如果医疗补助计划发生潜在变化，产前检测面临的风险最大，但他提到，历史上一直不愿在这一领域调整报销政策的州立法机构可能会提供一定程度的保护。

.

。

'When we look at distribution in terms of Medicare, commercial, and Medicaid, and where in our products the Medicaid revenue falls, we don't think that we have a lot of exposure to Medicaid block grants or to other changes in Medicaid reimbursement,' Diaz said.

“当我们根据联邦医保、商业保险和医疗补助计划来查看我们的收入分布，以及我们的产品中医疗补助收入所占的位置时，我们认为我们对医疗补助整笔拨款或医疗补助报销的其他变化并没有太大的风险，”迪亚兹说。

Diaz also downplayed concerns about the potential effects of broader market disruption, stating that at this time, Myriad has 'no intention' of changing its current investment strategies.

迪亚兹还淡化了对更广泛市场动荡潜在影响的担忧，他表示，目前，Myriad“无意”改变其当前的投资策略。

For full-year 2024, Myriad reported $837.6 million in revenues, up 11 percent from $753.2 million in 2023 and marking the second consecutive year of double-digit revenue growth.

2024年全年，Myriad报告收入为8.376亿美元，较2023年的7.532亿美元增长了11%，标志着连续第二年实现两位数的收入增长。

Full-year hereditary cancer testing revenues rose 11 percent to $364.5 million from $327.8 million, while tumor profiling test revenues fell 7 percent to $125.8 million from $135.6 million in 2023. Prenatal test sales rose 17 percent in 2024 to $177.1 million from $151.3 million a year ago, and pharmacogenomics test revenues were up 23 percent to $170.2 million from $138.5 million.

全年遗传性癌症检测收入增长了11%，从3.278亿美元增至3.645亿美元，而肿瘤谱型检测收入下降了7%，从2023年的1.356亿美元降至1.258亿美元。2024年，产前检测销售额增长了17%，从一年前的1.513亿美元增至1.771亿美元，药物基因组学检测收入增长了23%，从1.385亿美元增至1.702亿美元。

.

。

The company's full-year R&D spending rose 28 percent to $113.4 million from $88.7 million in 2023, while its SG&A expenses fell 2 percent to $560 million from $572.9 million a year earlier.

公司的全年研发支出从2023年的8870万美元增长了28%，达到1.134亿美元，而其销售、一般和管理费用则同比下降了2%，从5.729亿美元降至5.6亿美元。

The company more than halved its full-year net loss to $127.3 million, or $1.41 per share, from $263.3 million, or $3.18 per share in 2023. On an adjusted basis, Myriad reported full-year EPS of $.14.

公司将其全年净亏损从2023年的2.633亿美元（每股3.18美元）大幅减少了一半以上，降至1.273亿美元（每股1.41美元）。按调整后计算，Myriad报告全年每股收益为0.14美元。

Myriad ended the quarter with $102.4 million in cash and cash equivalents.

Myriad在本季度末拥有1.024亿美元的现金及现金等价物。

The company said it anticipates full-year 2025 revenue of $840 million to $860 million, reflecting annual growth of 9 percent to 11 percent, excluding the potential impact from a Q4 change in UnitedHealthcare's

该公司表示，预计2025年全年收入将达到8.4亿美元至8.6亿美元，反映出不包括第四季度UnitedHealthcare变更潜在影响的年增长率为9％至11％。

pharmacogenomics medical policy

药物基因组学医疗政策

and divested businesses.

并剥离了业务。

First quarter revenue is expected to be between $196 million and $204 million, while the company expects a Q1 loss per share of $.04 to $.08.

第一季度营收预计在1.96亿美元至2.04亿美元之间，而公司预计每股亏损为0.04至0.08美元。

Myriad said that it continues to pursue a resolution with UnitedHealthcare that allows for its commercial and managed Medicaid enrollees to have continued access to GeneSight, but that there is no guarantee that these efforts will be successful. As such, the company has streamlined operations and cost structure accordingly..

Myriad表示，它将继续寻求与联合健康保险的解决方案，以使其商业和管理的医疗补助计划参保人能够继续使用GeneSight，但无法保证这些努力会成功。因此，公司已相应地简化了运营和成本结构。